<DOC>
	<DOC>NCT01949077</DOC>
	<brief_summary>The purpose of the study is to determine differences in levels of serum chemokines from patients undergoing treatment with Boceprevir. The aim is to determine if non-responders have significantly different levels of chemokines than responders.</brief_summary>
	<brief_title>Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.</brief_title>
	<detailed_description>Patients undergoing standard of care at the UNC Liver Center are consented for collection of an additional serum sample under the UNC Liver Center serum and tissue bank study. These samples will be used to analyze differences in serum chemokines across responders and non-responders.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>All adult patients (age 18 or older) treated with an antiviral Hepatitis C treatment regimen that includes Boceprevir. Inability to provide informed consent for a serum sample enrolled in the University of North Carolina Liver Center serum bank. No pre and post serum sample available within 6 months of the treatment period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Observational study</keyword>
	<keyword>Biomarkers of treatment response</keyword>
</DOC>